Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
15 May 2024 | Story Valentino Ndaba | Photo Supplied
Heaters
Embrace the warmth of safety: Stay cozy with approved quartz heaters such as the Goldair GHQ-100G, keeping our campus secure and snug.

As winter approaches, the University of the Free State (UFS) is expecting increased heater usage. The Department of University Estates is proactively addressing this surge in energy demand caused by colder weather to safeguard our campuses and help mitigate the risk of loadshedding, ensuring uninterrupted operations for our staff and students.

By addressing the surge in energy demand caused by colder weather and promoting energy-efficient practices, UFS aims to play its part in alleviating the strain on the power system and contributing to national efforts to mitigate loadshedding.

With South Africa enjoying a recent break from loadshedding, Nicolaas Esterhuysen, Director of Engineering Services, stresses the importance of wise electricity usage to prevent outages and maintain safety. “During this uninterrupted power supply, it’s crucial to be mindful of our electricity usage, especially regarding heating in winter,” Esterhuysen emphasises. “By adopting energy-efficient practices, we contribute to the university’s energy-efficiency goals and create a safer environment."

In line with promoting energy efficiency, the Office for Occupational Health and Safety (OHS) is rolling out a comprehensive campaign to remove unauthorised heaters, minimising fire risks in residential and office areas.

Thato Block, Deputy Director of OHS, explains: “With the structural fire season approaching, UFS is prioritising campus safety. As colder weather looms, heaters and other warming devices will be in high demand, prompting preemptive action. OHS and the Electrical workshop will commence removing unauthorised heaters from residences and offices starting May 2024.”

Guidelines for heater usage

To ensure compliance and safety, UFS has established specific guidelines for electrical heater usage on its premises. The Standard Operating Procedure (SOP) outlines permissible and prohibited heater types, along with safety measures.

According to the SOP, only quartz heaters meeting specific criteria, such as the Goldair GHQ-100G model, are permitted on campus. These heaters are designated for offices without air conditioning, prioritising energy efficiency and safety. Furthermore, heaters are not permitted in residences due to the presence of centralised heating systems.

Prohibited models like bar, fan and oil heaters are strictly banned due to their high energy consumption and fire risks. Any unauthorised heaters found on campus will be confiscated to prevent electrical circuit overload and ensure emergency power system reliability.

In addition to regulating heater types, the UFS has implemented a stringent purchasing procedure overseen by the Department of University Estates Electrical Engineers. Approval is required before requisitioning heaters, with only quartz heaters meeting purchase criteria. This proactive approach aims to effectively manage electricity consumption, especially during peak demand periods in winter.

Safety precautions

The UFS community is reminded to exercise caution when using heaters, including maintaining a clutter-free environment around the device, and avoiding covering it. It’s also important to ensure adequate distance between the heater and flammable materials, switch off heaters when unattended, and disconnect them from power sources during prolonged periods of non-use.

Commitment to campus safety

The UFS remains committed to prioritising the safety and well-being of its community. Through proactive measures and fostering safety awareness, the university aims to create a secure environment conducive to teaching and learning throughout the year.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept